Printer Friendly

BD Biosciences' Clontech finds a buyer.

Otsu, Japan 7/1/05; Franklin Lakes, NJ 7/1/05--Takara Bio, a unit of Japanese conglomerate Takara, has entered into a definitive agreement to acquire the Clontech unit for $60 million from Becton, Dickinson and Company's BD Biosciences. Based in Palo Alto, California with 190 employees, Clontech Laboratories develops, manufactures and markets biological products for the life science market, specializing in molecular biology. In fiscal 2004, Clontech posted sales of around $60 million. According to Takara Bio, Clontech's products for gene function and protein interaction analysis will complete Takara Bio's molecular biology products, such as restriction enzymes and PCR enzymes. Takara also expects the acquisition to enhance its European and US business. In fiscal 2004, approximately 85% of Takara Bio's sales were in Japan, while 70% of Clontech's sales were in the US and Europe. The acquisition is also expected to strengthen Takara Bio's US research capabilities. In fiscal 2004, Takara Bio's research reagent revenues totaled [yen] 11.8 billion ($10.9 million). The acquisition is expected to close by August 2005 and will be made through a US-owned subsidiary of Takara Bio.

BD announced it was putting Clontech up for sale last fall (see IBO 10/15/ 04) and took a pre-tax charge of $124 million in fiscal 2004 to write down Clontech's net assets to fair value. For the first six months of fiscal 2005 ended March 31, Clontech sales fell 8.4% to $28.7 million. The acquisition should help Takara Bio expand its US business. Last year, Takara Bio acquired its US subsidiary. Also in 2004, Takara Bio went public on the Tokyo stock exchange.
COPYRIGHT 2005 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CLONTECH Laboratories Inc., Takara Bio Inc.
Publication:Instrument Business Outlook
Article Type:Brief Article
Geographic Code:1USA
Date:Jul 15, 2005
Previous Article:Danaher to buy Leica for $550 million.
Next Article:Cameca adds to SIMS product line.

Related Articles
Idun licenses research rights to its apoptosis technology exclusively to Becton Dickinson Biosciences.
BD to sell Clontech.
Second quarter Life Science revenue growth slows.
Takara Bio Chinese Subsidiary to Expand Lines of Business, Files Chinese Clinical Trial Application.
New patent suits address groundbreaking techniques.
Takara Bio Grants Transgenomic License for LA-PCR Technology.
Invitrogen and Clontech settle patent suit.
The bottom line.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters